RedHill Biopharma Adjourns Annual Shareholder Meeting
Ticker: RDHL · Form: 6-K · Filed: Sep 17, 2024 · CIK: 1553846
| Field | Detail |
|---|---|
| Company | Redhill Biopharma Ltd. (RDHL) |
| Form Type | 6-K |
| Filed Date | Sep 17, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: meeting-adjournment, shareholder-meeting
TL;DR
RedHill Biopharma postponed its shareholder meeting, new date TBD.
AI Summary
RedHill Biopharma Ltd. announced the adjournment of its Annual General Meeting of Shareholders, originally scheduled for September 2024. The meeting has been postponed to a new date, which will be announced in a subsequent filing. This adjournment is to allow for further consideration of certain matters.
Why It Matters
Shareholders may be awaiting decisions or updates that are now delayed, potentially impacting investment strategies or company direction.
Risk Assessment
Risk Level: low — The filing is procedural, announcing the adjournment of a meeting, and does not contain new financial or operational risks.
Key Players & Entities
- RedHill Biopharma Ltd. (company) — Registrant
- September 2024 (date) — Original meeting date
FAQ
What was the original date of the Annual General Meeting of Shareholders?
The Annual General Meeting of Shareholders was originally scheduled for September 2024.
Why was the Annual General Meeting of Shareholders adjourned?
The filing states the adjournment is to allow for further consideration of certain matters, but does not specify what those matters are.
Has a new date for the Annual General Meeting of Shareholders been set?
No, the filing indicates that a new date will be announced in a subsequent filing.
What is the principal executive office address of RedHill Biopharma Ltd.?
The principal executive offices are located at 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel.
Under which form does RedHill Biopharma Ltd. file its annual reports?
RedHill Biopharma Ltd. files its annual reports under Form 20-F.
Filing Stats: 391 words · 2 min read · ~1 pages · Grade level 8.3 · Accepted 2024-09-17 09:13:19
Filing Documents
- zk2432043.htm (6-K) — 12KB
- 0001178913-24-003083.txt ( ) — 13KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: September 17, 2024 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer